Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02QQE
|
|||
| Drug Name |
NKTR 214
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1] | |
| Sarcoma [ICD-11: 2A60-2C35; ICD-10: C81-C86; ICD-9: 202.8] | Phase 2 | [2] | ||
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1/2 | [3] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [3] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 1/2 | [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1/2 | [2] | ||
| Company |
Nektar Therapeutics San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 2 receptor beta (IL2RB) | Target Info | Agonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Measles | ||||
| HTLV-I infection | ||||
| Transcriptional misregulation in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| SHP2 signaling | ||||
| IL2-mediated signaling events | ||||
| IL2 signaling events mediated by PI3K | ||||
| IL2 signaling events mediated by STAT5 | ||||
| Downstream signaling in naï | ||||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-2 signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-2 Signaling Pathway | |||
| Inflammatory Response Pathway | ||||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.